Cargando…

Primary or secondary antifungal prophylaxis in patients with hematological maligancies: efficacy and damage

BACKGROUND: Patients with hematological malignancies often develop febrile neutropenia (FN) as a complication of cancer chemotherapy. Primary or secondary antifungal prophylaxis is recommended for patients with hematological malignancies to reduce the risk of invasive fungal infection (IFI). This st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gedik, Habip, Şimşek, Funda, Yıldırmak, Taner, Kantürk, Arzu, Arıca, Deniz, Aydın, Demet, Demirel, Naciye, Yokuş, Osman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011927/ https://www.ncbi.nlm.nih.gov/pubmed/24855365 http://dx.doi.org/10.2147/TCRM.S59683

Ejemplares similares

Bloodstream infections in patients with hematological malignancies: which is more fatal – cancer or resistant pathogens?
por: Gedik, Habip, et al.
Publicado: (2014)

Could Neutrophil CD64 Expression Be Used as a Diagnostic Parameter of Bacteremia in Patients with Febrile Neutropenia?
por: Efe İris, Nur, et al.
Publicado: (2017)

Community-acquired intracranial suppurative infections: A 15-year report
por: Yıldırmak, Taner, et al.
Publicado: (2014)

Etiological causes of pancytopenia: A report of 137 cases
por: Yokuş, Osman, et al.
Publicado: (2016)

Jak-2 mutation frequency in patients with thrombocytosis
por: Yokus, Osman, et al.
Publicado: (2018)

The expenditures related to the use of antifungal drugs in patients with hematological cancers: a cost analysis
por: Gedik, Habip
Publicado: (2015)

Janus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey
por: Yildiz, Ismail, et al.
Publicado: (2017)

Antibiotic resistance status and its costs in hematological patients: A two-year analysis
por: Gedik, Habip
Publicado: (2017)

Charlson Comorbidity Index (CCI) in Diffuse Large B-cell Lymphoma: A New Approach in a Multicenter Study
por: Eren, Rafet, et al.
Publicado: (2022)

Complete mitochondrial genomes of two rockfish: Sebastes maliger and Sebastes norvegicus (Scorpaenidae, Scorpaeniformes)
por: Campbell, Jillian R., et al.
Publicado: (2022)

How Does 2016 WHO Criteria for Polycythemia Vera Contribute to Our Daily Practice? A Single-Center Study from Turkey
por: Eren, Rafet, et al.
Publicado: (2020)

Dermatologic manifestations of multisystem inflammatory syndrome in children during the COVID-19 pandemic()
por: Baykal Selçuk, Leyla, et al.
Publicado: (2023)

Comparison of Risk Category Predictions of Framingham Risk Score (FRS), Atherosclerotic Cardiovascular Disease Risk Score (ASCVD), Systematic Coronary Risk Evaluation (SCORE) and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) in HIV Infected Patients
por: Korten, Volkan, et al.
Publicado: (2017)

Antifungal Prophylaxis
por: Johnson, Douglas Clark, et al.
Publicado: (2021)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

The Obesity Controversy: Does It Impact Treatment Response in Diffuse Large B-Cell Lymphoma?
por: Atak, Suheyla, et al.
Publicado: (2023)

Reply: Antifungal Prophylaxis
por: Pennington, Kelly M., et al.
Publicado: (2021)

Secondary Antifungal Prophylaxis in Hematological Malignancy Patients with Previous Invasive Fungal Disease: A Retrospective Analysis
por: Liu, Mingjuan, et al.
Publicado: (2014)

Systemic Antifungal Prophylaxis in Patients Hospitalized in Hematology Units in France: The AFHEM Cross-Sectional Observational Study
por: Gangneux, Jean-Pierre, et al.
Publicado: (2018)

Factors Influencing the Safety and Efficiency of Antifungal Prophylaxis with Posaconazole in Children with Hematological Diseases: From Genetics to Polypharmacotherapy
por: Sienkiewicz-Oleszkiewicz, Beata, et al.
Publicado: (2019)

Use of antifungal drugs in hematology
por: Nucci, Marcio
Publicado: (2012)

Antifungal Prophylaxis in Immunocompromised Patients
por: Vazquez, Lourdes
Publicado: (2016)

Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology–oncology patients: a retrospective cohort study
por: Kung, Hsiang-Chi, et al.
Publicado: (2014)

Money and transmission of bacteria
por: Gedik, Habip, et al.
Publicado: (2013)

Network meta-analysis of triazole, polyene, and echinocandin antifungal agents in invasive fungal infection prophylaxis in patients with hematological malignancies
por: Zeng, Huilan, et al.
Publicado: (2021)

Antifungal prophylaxis in critically ill patients
por: Silvestri, Luciano, et al.
Publicado: (2008)

Hepatitis B sero-prevalence among hematology patients: importance of Anti-HbcAb and efficiency of antiviral prophylaxis
por: Kantar, Funda Ugur, et al.
Publicado: (2022)

Predictors of fatality in pandemic influenza A (H1N1) virus infection among adults
por: Ergönül, Önder, et al.
Publicado: (2014)

Case Report: Infectious prophylaxis in hematological malignancies
por: Passucci, Mauro, et al.
Publicado: (2023)

Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Network Meta-analysis
por: Wang, Jing, et al.
Publicado: (2020)

Antifungal Resistance and Predictors of Response in Patients with Hematologic Malignancy
por: Wey, Shiuan (Shannon), et al.
Publicado: (2017)

Recommendations on the use of azole antifungals in hematology-oncology patients
por: Azanza, José Ramón, et al.
Publicado: (2023)

Current evidence of antifungal prophylaxis and therapy in pediatric patients
por: Giacchino, Mareva, et al.
Publicado: (2011)

Clinical practice update of antifungal prophylaxis in immunocompromised children
por: Ramos, José Tomás, et al.
Publicado: (2019)

Micafungin as antifungal prophylaxis in non-transplanted haemotological patients
por: Villaescusa, Teresa, et al.
Publicado: (2020)

Metabolic Changes and Serum Ghrelin Level in Patients with Psoriasis
por: Ucak, Haydar, et al.
Publicado: (2014)

2737. Real World Evaluation of Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant (aHSCT) Patients, Is Routine Antifungal Prophylaxis Needed?
por: Perreault, Sarah, et al.
Publicado: (2023)

Tc-99m Labeled HMPAO white Blood Cell Scintigraphy in Pediatric Patients
por: Aydın, Funda, et al.
Publicado: (2012)

Economic considerations of antifungal prophylaxis in patients undergoing surgical procedures
por: Cataldo, Maria Adriana, et al.
Publicado: (2011)

Fosfluconazole for Antifungal Prophylaxis in Very Low Birth Weight Infants
por: Takahashi, Daijiro, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_muc0malsjt9t8lbh4b1dlfvkt2